In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT(2A) receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2- amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3- yl]thiazole (NRA0045)

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 56-63

  Okuyama, Shigeru ^a   Chaki, Shigeyuki ^a   Yoshikawa, Ryoko ^a   Suzuki, Yoshiko ^a   Ogawa, Shin Ichi ^a   Imagawa, Yasuko ^a   Kawashima, Naoya ^a   Ikeda, Yoko ^a   Kumagai, Toshihito ^a   Nakazato, Atsuro ^a   Nagamine, Masashi ^b   Tomisawa, Kazuyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b NIHON NOHYAKU CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 3 PYRROLIDINYL]THIAZOLE; 2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL]PYRROLIDIN 3 YL]THIAZOLE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENOSINE A1 RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; EMONAPRIDE; FANANSERIN; HALOPERIDOL; METHAMPHETAMINE; NEUROTRANSMITTER RECEPTOR; NORADRENALIN; PENTAZOCINE; SEROTONIN 1A RECEPTOR; SEROTONIN 1C RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SPIPERONE; TRYPTAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CLONIC SEIZURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG POTENCY; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; HUMAN CELL; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LETHALITY; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STEREOTYPY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CATALEPSY; COS CELLS; DOPAMINE ANTAGONISTS; HUMANS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NOREPINEPHRINE; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STEREOTYPED BEHAVIOR; THIAZOLES;

EID: 15644375195     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. 2 receptor blocking agent. Curr. Ther. Res. 40: 492-499, 1986.
2. 2 receptor mRNA. Brain Res. 564: 203-219, 1991.
3. 4 antagonists. J. Med. Chem. 39: 1946-1948, 1996.
4. 2 blockade by typical and atypical neuroleptics. Lancet 339: 497, 1992.
5. CASEY, D. E.: Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99: S47-S53, 1989.
6. CHAKI, S., TANAKA, M., MURAMATSU, M. AND OTOMO, S.: NE-100, a novel potent ∂ ligand, preferentially binds to ∂1 binding sites in guinea pig brain. Eur. J. Pharmacol. 251: R1-R2, 1994.
7. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
8. CHOMCZYNSKI, P. AND SACCHI, N.: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159, 1987.
9. 2 receptor antagonist. Br. J. Pharmacol. 105: 27-36, 1992.
10. EVENDEN, J. L. AND RYAN, C. N.: Behavioral responses to psychomotor stimulant drugs: Localization in the central nervous system. In Psychotropic Drugs of Abuse, ed. by D. J. K. Balfour, pp. 1-21, Pergamon Press, New York, 1990.
11. 2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry 49: 538-544, 1992.
12. FELGNER, P. L., GADEK, T. R., HOLM, M., ROMAN, R., CHAN, H. W., WENZ, M., NORTHROP, J. P., RINGOLD, G. M. AND DANIELSEN, M.: Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84: 7413-7417, 1987.
13. 2 dopamine receptor isoforms. Nature (Lond.) 342: 928-926, 1991.
14. 4 receptors. Br. J. Pharmacol. 117: 1625-1632, 1996.
15. HOFFMAN, D. C. AND DONOVAN, H.: Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120: 128-133, 1995.
16. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 244: 685-693, 1988.
17. 5 receptor. J. Recept. Res. 13: 573-590, 1993.
18. KERWIN, R. W. AND COLLIER, D.: The dopamine D4 receptor in schizophrenia: An update. Psychol. Med. 26: 221-227, 1996.
19. 4 receptor. J. Med. Chem. 39: 1941-1942, 1996.
20. 2 receptor selectivity of dopamine receptor antagonists: Possible therapeutic implications. Eur. J. Pharmacol. 236: 483-486, 1993.
21. 2 antagonist. Mol. Pharmacol. 27: 600-611, 1985.
22. 4 receptor. Eur. J. Pharmacol. 273: R1-R3, 1995.
23. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with folin phenol reagent. J. Bio. Chem. 193: 265-275, 1951.
24. MANSOUR, A. AND WATSON, S. J.: Dopamine receptor expression in the central nervous system. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. V. Kupfer, pp. 207-219, Raven Press, New York, 1995.
25. MEGENS, A. A. H. P., AWOUTERS, F. H. L., SCHOTTE, A., MEERT, T. F., DUGOVIC, C., NIEMEGEERS, C. J. E. AND LEYSEN, J. E.: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114: 9-23, 1994.
26. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15: 2186-2191, 1995.
27. 4 receptor antagonists: Synthesis and structure-activity relationships of (S)-(+)-N-(1-benzyl-3-pyrrolidinyl)-5-chloro-4-[(cyclopropylcarbonyl)amine]-2- methoxybenzamide (YM-43611) and related compounds. J. Med. Chem. 39: 2764-2772, 1996.
28. OKUYAMA, S., IMAGAWA, Y., OGAWA, S., ARAKI, H., AJIMA, A., TANAKA, M., MURAMATSU, M., NAKAZATO, A., YAMAGUCHI, K., YOSHIDA, M. AND OTOMO, S.: NE-100, a novel sigma receptor ligand: In vivo test. Life Sci. 53: PL285-290, 1993.
29. 4 receptor: Sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol. 4: 137-146, 1992.
30. PEROUTKA, S. J., U'PRICHARD, D. C., GREENBERG, D. A. AND SYNDER, S. H.: Neuroleptic drug interactions with norepinephrine alpha-receptor bonding sites in the brain. Neuropharmacology 16: 549-556, 1977.
31. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340: 199-202, 1992.
32. 123I-IBZM SPET (single photon emission tomography). Psychological Med. 23: 791-797, 1993.
33. 2 receptor blocker. Drug Dev. Res. 8: 205-211, 1986.
34. 4 receptors. J. Med. Chem. 39: 1943-1945, 1996.
35. 4. Neuropsychopharmacology 7: 261-284, 1992.
36. SEEMAN, P.: Dopamine receptors: Clinical correlates. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. V. Kupfer, pp. 295-302, Raven Press, New York, 1995.
37. SEEMAN, P., CHAU-WONG, M., TEDESCO, J. AND WONG, K.: Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc. Natl. Acad. Sci. U.S.A. 72: 4376-4380, 1975.
38. 4 receptors elevated in schizophrenia. Nature (Lond.) 365: 441-445, 1993.
39. SEEMAN, P. AND VAN TOL, H. H. M.: Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15: 264-270, 1994,
40. 3) as a target for neuroleptics. Nature (Lond.) 347: 146-151, 1990.
41. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res. 681: 109-116, 1995.
42. TAKEBE, Y., SEIKI, M., FUJISAWA, J., HOY, P., YOKOTA, K., ARAI, K., YOSHIDA, M. AND ARAI, N.: SRα promoter: An efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus Type 1 long terminal repeat. Mol. Cell. Biol. 8: 466-472, 1988.
43. TAMMINGA, C. A., THAKER, G. K., BUCHANAN, R., KIRKPATRICK, B., ALPHS, D. L., CHASE, T. N. AND CARPENTER, W. T.: Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alteration with deficit syndrome. Arch. Gen. Psychiatry 49: 522-530, 1992.
44. 4 antagonist. J. Med. Chem. 39: 2435-2437, 1996.
45. TIMMERMANS, P. B. M. W. H., ALI, F. K., KWA, H. Y., SCHOOP, A. M. C., SLOTHORST-GRISDIJK, F. P. AND VAN ZWIETEN, P. A.: Identical antagonist selectively of central and peripheral alpha-adrenoceptors. Mol. Pharmacol. 20: 295-301, 1981.
46. 4 receptor with high affinity for antipsychotic clozapine. Nature (Lond.) 350: 610-614, 1991.
47. WAGSTAFF, A. J. AND BRYSON, H. M.: Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 4: 370-400, 1995.
48. WEINBERGER, D. R.: Schizophrenia and the frontal lobe. Trends Neurosci. 11: 367-370, 1988.